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central role and subsequently drives the dysregulation of 
the cytoskeletal protein, tau. The amyloid hypothesis is sup-
ported by a substantial body of scientific and clinical evi-
dence (2). AD is typified by the progressive A deposition 
in the brain parenchyma as both diffuse and dense-core 
plaques, starting in isocortical areas, followed by limbic and 
allocortical structures, and finally subcortical structures 
(3). A peptide is generated by sequential cleavage of the 
amyloid precursor protein (APP) by the  and  secretases, 
yielding a heterogeneous pool of A species with different 
lengths, most prominently those of 40 or 42 amino acids in 
length. The A(1-42) species is more hydrophobic and 
highly self-aggregating, and is the principal species that is 
initially deposited in the brain of AD patients. APP can also 
be processed in a nonamyloidogenic pathway mediated by 
-secretase activity, generating a soluble APP fragment 
(sAPP), which is considered to have beneficial effects on 
neurons (4, 5). Genetically inherited familial forms of AD 
are caused by mutations in APP or in -secretase that favor 
A(1-42) generation, followed by aggregation and deposi-
tion. On the other hand, patients with “sporadic” late-onset 
AD, exhibit an impairment of A clearance from the brain, 
likely underlying the pathological A accumulation ob-
served in this type of patient (6, 7). Thus, perturbation of 
A homeostasis caused by either increased production (fa-
milial AD) or impaired clearance (sporadic late-onset AD) 
of A peptides leads to the pathological accumulation of 
this peptide in the form of toxic A oligomers, disrupting 
synaptic function and plasticity, which is postulated to un-
derlie the cognitive deficits observed in this disease. The 
deposition of A in the form of plaques results in neuritic 
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Alzheimer’s disease (AD) is a progressive neurodegen-
erative disorder and the leading cause of dementia in the 
elderly. There is an urgent need for the development of 
novel and effective therapeutic strategies for the preven-
tion and/or treatment of AD, given the personal and finan-
cial burdens associated with this disease (1). Although 
several hypotheses have been proposed, the dominant 
model of AD pathogenesis was put forward more than 20 
years ago, in which the amyloid- (A) peptide plays a 
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dystrophy (8) and triggers glial activation leading to the 
induction of a robust inflammatory response. This cascade 
of events further leads to neuronal injury and hyperphos-
phorylation and aggregation of tau protein, culminating in 
widespread synaptic dysfunction and neuronal loss (2). 
Thus, therapeutic strategies aiming to decrease A burden, 
by increasing clearance or reducing A generation, were 
expected to have a beneficial effect in AD patients, al-
though this has yet to be demonstrated in clinical trials. 
New therapeutic options that are not limited to modula-
tion of A levels are now under development.
Because the exact etiology of sporadic late onset AD is 
unknown, most of the animal models that have been devel-
oped to study this disease rely on the utilization of muta-
tions related to familial forms of AD. The majority of 
animal models mentioned in this review are based on trans-
genic mice carrying mutated human APP and presenilin-1 
(PSEN1) transgenes with a neuron-specific expression, re-
sulting in increased A production and accumulation, ulti-
mately leading to the onset and progression of AD-like 
pathology. Some models only carry one transgene with a 
particular familial AD mutation, such as the case of the 
APP23 and Tg2576 mouse models, which express human 
APP harboring the Swedish mutation (KM670/671NL) 
(APPswe) (9, 10), and the APPV717I model, which ex-
presses the human APP with the London mutation (V717I) 
(11). Other models were developed to exhibit two familial 
AD mutations in a particular transgene, such as the 
APPswe,ind mice that express the human APP not only 
bearing the Swedish mutation, but also the Indiana mu-
tation  (V717F)  (12,  13).  Furthermore,  the  APPswe/
PSENd1E9 mouse model carries APPswe together with the 
human PSEN1 containing the AD-related deletion of exon 
9 (14, 15). Another popular model is 5XFAD mice, which 
express the human APP harboring three familial AD muta-
tions, the Swedish, Florida (I716V), and London muta-
tions, together with PSEN1 containing two familial AD 
mutations, M146L and L286V (16). Some mouse models 
were also generated to reflect the tau-related pathology of 
AD, namely, the P301S mouse model, which expresses tau 
protein bearing the P301S familial AD-related mutation 
(17), and other models that incorporate both features of 
tau and A pathologies, such as the case of the 3xTg-AD 
mouse model, which carries three familial AD mutations, 
as it expresses the APPswe, the human P301L tau mutation, 
and PSEN1 harboring the M146V mutation (18, 19). The 
disease onset and progression is specific for each model, 
and it is a crucial factor to take into consideration when 
comparing studies and testing new therapeutic strategies.
NUCLEAR RECEPTORS
Nuclear receptors (NRs) belong to a superfamily of 
ligand-activated transcription factors that regulate the ex-
pression of a large number of genes involved in a wide 
variety of biological processes, regulating energy and lipid 
metabolism in response to environmental and dietary 
changes (20). For the last 10–15 years, numerous studies 
demonstrated that the pharmacological targeting of par-




II family of NRs, a group that encompasses nonsteroid NRs 
that form obligate heterodimers with RXR. The heterodi-
meric receptors bind to sequence-specific DNA elements 
positioned in the enhancers and promoters of their target 
genes, and act to directly regulate gene transcription. The 
heterodimeric receptors are retained in the nucleus re-
gardless of their ligand binding status (21). Importantly, 
LXR and PPAR heterodimers with RXR are considered to 
be “permissive,” meaning that the heterodimer is activated 
by ligation of either member of the receptor pair and, 
when simultaneously ligated, it can respond in an additive 
or synergistic fashion. In contrast, heterodimers of RAR 
with RXR are “conditionally permissive;” they are not acti-
vated by RXR ligands alone; it is the binding of a RAR li-
gand that activates the dimer and subsequently allows the 
binding of RXR ligands, increasing the transcriptional po-
tential of RAR. There are also “non-permissive” RXR het-
erodimers, such as the thyroid hormone receptor, which 
only respond to ligands of the nonpermissive binding part-
ner and not RXR ligands (22). Importantly, in the absence 
of  ligand  binding,  the  RXR  heterodimers  are  bound  to 
DNA and function as transcriptional repressors to silence 
gene expression. This repression mechanism is mediated 
by an interaction with corepressor complexes that contain 
the NR corepressor (NCoR) or the silencing mediator of 
retinoic acid thyroid hormone receptors (SMRT), together 
with HDAC3. Upon the binding of a ligand, the heterodi-
mer changes its conformation resulting in the dismissal of 
the corepressor complex and the association with tran-
scriptional coactivators, such as p300 and members of the 
steroid receptor coactivator (SRC) subfamily, which cata-
lyzes the assembly of large protein complexes mediating 
the induction of gene transcription (23). Additionally, 
other repression mechanisms mediated by these NRs that 
do not include direct binding do DNA (transrepression) 
have been reported in macrophages. Upon binding to 
their ligands, monomers of PPAR  and LXRs can be  su-
moylated, which leads them to interact and prevent the 
clearance of NCoR corepressor complexes from chroma-
tin. This mechanism is responsible for maintaining the re-
pression of a particular subset of genes that are activated by 
the nuclear factor-B (NF-B) in response to inflammatory 
signals, most prominently in immune cells (23).
The role of NRs in the brain is not as well understood as 
in other periphery organs. However, it is clear that these 
receptors regulate a wide array of processes, such as lipid 




lipogenesis, and inflammation. These receptors are activated 
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by  endogenous  oxysterols.  There  are  two  LXR  isoforms, 
LXR and LXR, and both are expressed in the brain, al-
though LXR exhibits the highest and most widespread 
expression pattern in this organ (24). LXR double knock-
out mice suffer from several brain abnormalities, including 
excessive lipid deposition, proliferation of astrocytes, and 
extensive neuronal loss (25). LXR-specific knockout mice 
also exhibit lipid accumulation, motor neuron degenera-
tion, and astrogliosis (26). Both genetic models highlight 
the critical role of LXRs in the brain.
PPARs
In general, PPARs act as lipid sensors and regulate 
whole body metabolism and energy homeostasis. Fatty ac-
ids and other lipids are endogenous ligands of the PPARs 
(27). A recent study analyzed the PPAR expression pat-
tern in the adult mouse and human brain, and it revealed 
that all PPAR isoforms are more highly expressed in neu-
rons than other cell types. The order of abundance in the 
brain was found to be PPAR/ > PPAR  PPAR (28), 
which is in line with previous findings (29). It is notewor-
thy, however, that the authors did not report any expres-
sion analysis in oligodendrocytes, but solely in neurons, 
astrocytes, and microglia, although it has been reported 
that PPARs have relevant biological actions in oligoden-
drocytes (30). PPARs have a variety of roles in the brain. 
PPAR has been widely associated with anti-inflammatory 
response, neuroprotection, neuronal differentiation, and 
neuronal function (31, 32). PPAR has been related to 
the regulation of energy homeostasis (33), synaptic func-
tion (34), neuroprotection, and anti-inflammatory re-
sponse (35). PPAR/ is involved in neuroprotection, 
astroglial differentiation, oligodendrocyte differentiation, 
and myelination (36).
RARs
The functions of RARs in the brain have not been stud-
ied as extensively as the other NRs. Nonetheless, RARs 
seem to play a role related to cognitive function, neuro-
nal differentiation, and locomotion in coordination with 
RXRs (37). It has also been suggested that RARs are im-
portant regulators of sleep and the circadian cycle (38). 
There are three isoforms, RAR, RAR, and RAR. These 
receptors are activated by vitamin A (all-trans retinol) 
and other retinoids (37). RARs are expressed through-
out several regions in the adult brain, and the expression 
profile seems to be sex-specific, with each isoform exhib-
iting its own unique expression pattern (39, 40). Using 
genetic models for these receptors, it was demonstrated 
that mice lacking RAR exhibit cognitive deficits associ-
ated with impaired long-term depression and long-term 
potentiation (41). Knockout of RAR revealed that this 
receptor is required for the homeostatic synaptic plastic-
ity mediated by all-trans retinoic acid, highlighting the 




to dimerize with other type II NRs, activating many differ-
ent  genes  and  pathways.  Additionally,  RXRs  are  able  to 
switch between a homotetramer and homodimer structure, 
modulating  DNA  architecture  (22).  Although  RXR  ho-
modimers have been shown to possess the ability to regu-
late PPAR metabolic pathways in vivo (43), only a small 
number of targets have been reported to be modulated by 
these homodimers, namely the chemokine (C-C motif) li-
gands 6 and 9 (44), and p21 (45). There are three isoforms 
of these receptors, RXR, RXR, and RXR. RXRs are ex-
pressed in several regions of the adult brain, with specific 
patterns depending on the isoform and sex (39, 40). It is 
not clear what is the primary endogenous ligand(s) for 
these receptors. In spite of 9-cis-retinoic acid being initially 
proposed  to  be  the  endogenous  ligand  for RXR,  several 
inconsistencies raised many doubts about this assumption. 
Moreover, phytanic acid and n-3 polyunsaturated fatty ac-
ids, such as the docosahexaenoic acid, have also been iden-
tified as RXR ligands (46).
NRs AND AD
NRs have been extensively investigated in animal models 
of CNS disorders, and agonists of these receptors have a 
broad range of salutary effects in murine models of AD, 
Parkinson’s disease, Huntington’s disease, amyotrophic 
lateral sclerosis, multiple sclerosis, stroke, and aging. A list 
of studies reported in the last 10–15 years and a summary 
of their major results arising from the pharmacological tar-
geting  of  LXRs,  PPARs,  RXRs,  and  RARs  in  AD  animal 
models are listed in Table 1. Overall, although there are 
inconsistencies among some reports, these NRs seem to be 
promising therapeutic targets for AD. It is likely that their 
beneficial effects do not rely on one particular mechanism, 
but rather on an array of different pathways, in some cases 
cell type-specific, which is in line with the fact that AD is a 
multifactorial disease. The mechanisms that have been de-
scribed, so far, as underlying the beneficial effects of these 
NRs can be systematized into four categories: A clearance; 
A generation; anti-inflammatory mechanisms; and neuro-
nal function (Fig. 1). Although some of these pathways are 
surely intertwined, many reports were able to pin-point, 
very specifically, the mechanisms through which NRs elic-
ited their effects in the brain.
A clearance
The stimulation of A clearance is one of the most popu-
lar strategies to ameliorate AD pathology. NRs are able to 
induce A clearance primarily by stimulating its enzymatic 
degradation, either extracellularly or through microglial 
phagocytosis. The clearance of soluble forms of A from 
the brain is regulated by apoE (47). Interestingly, the ma-
jor source of apoE in the brain is astrocytes (48), and its 
expression and secretion are under the regulation of 
LXR:RXR heterodimers (49). Jiang et al. (50) were the first 
to demonstrate that ABCA1-mediated lipidation of apoE 
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stimulates proteolytic degradation of A through microg-
lial neprilysin and extracellular insulin-degrading enzyme 
(IDE). Because apoE and ABCA1 are canonical targets of 
LXR,  the authors  treated  the AD mouse model, Tg2576, 
with the LXR agonist, GW3965, to induce apoE lipidation. 
This treatment led to a marked reduction in both A 
plaque burden and soluble A, together with a dramatic 
improvement in contextual memory. Importantly, the abil-
ity of microglial cells to degrade A was apoE isoform de-
pendent, with isoform E2 being the most effective, followed 
by E3, and the less effective E4, which is also the more 
poorly lipidated isoform (50). This work provided a puta-
tive mechanistic explanation for the fact that the APOE4 
allele is the major genetic risk factor for late-onset AD (2). 
Importantly, this report also paved the way for the follow-
ing development of novel apoE-directed therapeutics for 
AD using NR agonists, such as for the case of the RXR ago-
nist,  bexarotene  (51). The  advantage of  using RXR ago-
nists  relies  on  the  activation  of  both  LXRs  and  PPARs. 
PPAR is also able to increase apoE and ABCA1 in the 
brains of AD animal models through the targeted increase 
in  LXR  expression  (52).  Additionally,  PPAR has been 
shown to induce IDE expression in neurons (53), and the 
A degrading activity of an IDE-like metalloproteinase 
(54). PPAR/ activation in the AD mouse model, 5XFAD, 
drives the expression of neprilysin and IDE (55), which can 
also contribute to an increased clearance of A. Similarly, 
RAR was shown to increase the expression of neprilysin 
and IDE, and stimulate microglia-mediated A clearance 
(56). Interestingly, these authors also observed an increase 
in microglial apoE expression upon activation of RAR. 
Compelling evidence indicates that NR activation stimu-
lates the phagocytic clearance of deposited forms of amy-
loid, resulting in the rapid reduction of plaque burden in 
murine models of AD (51, 52, 57–60). NR induction of A 
phagocytosis by brain myeloid cells seems to rely on the 
expression of the phagocytic receptors, Axl and MerTK, 
both of which are induced by the RXR agonist, bexarotene. 
Furthermore, inhibiting the MerTK receptor abrogated 
the induction of phagocytosis by bexarotene in brain slices 
of the AD mouse model, APPswe/PSEN1dE9 (57). Thus, it 
has been proposed that the induction of MerTK and Axl 
Fig. 1. Effects of NR activation in AD. The underlying mechanisms by which the activation of NRs exerts beneficial effects in AD are not 
completely understood. Nonetheless, a number of studies have been able to dissect some of these mechanisms, which seem to be cell 
type-specific, and can be grouped in four different classes: 1) A clearance: mainly through modulation of A phagocytosis and enzymatic 
degradation; 2) anti-inflammatory mechanisms: repression and induction of pro-inflammatory and anti-inflammatory genes, respectively; 3) 
A generation: modulation of APP processing by inhibiting BACE1 production or by shifting to the nonamyloidogenic pathway by induction 
of ADAM10, reducing A production in both cases; and 4) neuronal function: increased synaptic function, neurogenesis, dendritic develop-
ment, and protection against neuronal insults. The overall effect of a particular NR agonist likely arises from the modulation of several dif-
ferent pathways, rather than only one particular mechanism, and it is also likely that many of the different mechanisms reported for a specific 
NR might be, to some extent, related to each other. AICD, APP intracellular domain; NCoR/SMRT, NCoR/silencing mediator of retinoic 
acid thyroid hormone receptors; BRE, NF-B response element; NRE, NR response element; sAPP, soluble APP fragment.
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expression by bexarotene licenses phagocytic activity of 
plaque-associated myeloid cells, promoting plaque clear-
ance in AD. Additionally, PPAR activation has been shown 
to stimulate microglial A phagocytosis by increasing the 
expression of the scavenger receptor, CD36, and, interest-
ingly, the combined treatment with PPAR and RXR ago-
nists was shown to have an additive effect on A uptake by 
myeloid cells (58). Importantly, it has also been reported 
that LXR activation with TO901317 leads to an increase in 
microglial A phagocytosis through the induction of ABCA1 
and apoE specifically in astrocytes, which positively regu-
lates phagocytosis in microglia (59). Thus, the increase in 
the efficiency of A phagocytosis by brain myeloid cells me-
diated by NR agonists seems to be underlined by different 
cellular mechanisms in both myeloid cells, themselves, and 
also in surrounding nonmyeloid cells, depending on which 
NR is being targeted.
A generation
Another mechanism by which NRs are able to reduce A 
burden, is to suppress the generation of this peptide by 
modulation of APP processing. Recently, PPAR activation 
was shown drive the -secretase ADAM metallopeptidase 
domain 10 (ADAM10) expression, shifting APP processing 
toward the non-amyloidogenic pathway, decreasing A lev-
els and increasing sAPP (61). Knocking out PPAR from 
5XFAD mice exacerbated A deposition and, interestingly, 
the same effect was observed in Ppara/ mice, which ex-
hibited increased levels of endogenous A. Furthermore, 
it has been observed that PPAR represses -secretase 1 
(BACE1) promoter activity and expression (62), which 
might be explained, in part, by the induction of miR-
188-3p, which targets BACE1 (63). Additionally, the reduc-
tion of BACE1 expression and A levels, mediated by the 
PPAR coactivator-1 (PGC-1) (64) and by the NR inter-
acting protein-1 (RIP140) (65), are both PPAR-dependent, 
further supporting the role of this receptor in the modula-
tion of A production. Moreover, RAR and RAR are also 
able to lower A generation by driving ADAM10 expres-
sion, which leads to an increase in sAPP as well (65). 
Interestingly, in vitro and in vivo data also support a mech-
anism by which LXR leads to a decrease in A production. 
This mechanism is dependent on the upregulation of 
ABCA1, but possibly not dependent on cholesterol efflux 
(66, 67).
Anti-inflammatory mechanisms
The NRs act broadly to suppress pro-inflammatory gene 
expression, and many of the salutary actions of NR agonists 
arise from their anti-inflammatory actions. AD-associated 
neuroinflammation is primarily driven by microglia, the 
resident myeloid cells in the brain, and escalates with dis-
ease progression. Microglia are responsible for the produc-
tion of a diverse range of pro-inflammatory cytokines and 
chemokines and other inflammatory mediators (68). Apart 
from resident microglia, it has been proposed that there is 
also infiltration of peripherally derived monocytes or mac-
rophages into the AD brain, also contributing to the patho-
physiology of the disease (69). Both the brain resident or 
peripherally derived myeloid cells respond to NR agonists 
by switching from an “activated” pro-inflammatory state to 
an “alternative activation” phenotype characterized by inhi-
bition of pro-inflammatory gene expression and induction 
of anti-inflammatory genes. Importantly, alternative activa-
tion phenotypes include the induction of genes associated 
with the resolution of inflammation, tissue repair, and in-
creased phagocytosis (69). Interestingly, it seems that there 
is still no consensus about the dominance of each of these 
states in AD and, in fact, analysis of brain samples from AD 
patients revealed the presence of markers from both activa-
tion states (70). These results suggest the presence of a het-
erogeneous population of immune effector cells, or even 
hybrid activation states, in the AD brain. Furthermore, as-
trocytes are also active players in AD-associated neuroin-
flammation. Similarly to microglia, A stimulates the 
activation of astrocytes and triggers inflammatory signaling 
cascades  (68).  Several  studies have  shown  that LXRs  and 
PPARs exhibit an anti-inflammatory effect in AD animal 
models (Table 1). Although the transrepression of NF-B 
target  genes  mediated  by  the  sumoylation  of  LXR  and 
PPAR was studied in peripheral macrophages (23), one 
would expect that a similar mechanism of transrepression 
of inflammation is likely to occur in microglia and astro-
cytes. Interestingly, it has been reported that the activation 
and  sumoylation  of  both  LXR  and  LXR in astrocytes 
leads them to interact with the signal transducer and activa-
tor of transcription 1 (STAT1), inhibiting the STAT1-medi-
ated inflammatory gene expression (71), which may also 
account  for  the anti-inflammatory effects of LXR  ligands. 
Additionally, the anti-inflammatory mechanisms of LXR in 
the context of AD pathology seem to be coupled to an in-
crease in microglia ability to phagocyte A (72).
Neuronal function
Several lines of evidence indicate that the activation of 
NRs is beneficial for neuronal function and development, 
as well as being neuroprotective. The identification of the 
mechanisms behind the modulation of neuronal function 
by NRs could be relevant in AD, allowing the identification 
of novel therapeutic targets. ChIP-seq and RNA-seq analysis 
of mice with targeted replacement of the endogenous mu-
rine apoE gene with the human APOE3 or APOE4 alleles 
(apoE3-TR and apoE4-TR mice) treated with the RXR ago-
nist, bexarotene, revealed that this compound stimulates 
genetic programs associated with neuronal differentiation 
and development in an APOE isoform-independent fash-
ion. This induction possibly occurs through epigenetic 
changes in these genes, namely, an enrichment in the his-
tone marker associated with active promoter, H3K4me3, 
and a decrease in the marker related to promoter repres-
sion, H3K27me3 (73, 74). Bexarotene has been shown to 
increase the number of neuronal progenitors in the den-
tate gyrus of apoE3-TR and apoE4-TR mice and, more im-
portantly, it rescued compromised dendritic structures in 
the hippocampus of apoE4-TR mice (73), cognitive impair-
ment, and overall APOE4-driven brain pathology (75). In-
terestingly, the comparison of the RNA-seq data obtained 
from the brains of bexarotene-treated apoE3-TR and 
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APP/PS1dE9/apoE3-TR mice revealed that A accumula-
tion affects the bexarotene-elicited changes in the tran-
scriptome (74). Although bexarotene was shown to induce 
an upregulation of genes related to neurogenesis, neuro-
nal development, and neuroprotection in both genotypes, 
the genes that are downregulated by this compound clus-
ter in very distinct categories between genotypes. This is 
the case of genes related to the immune system and inflam-
matory response, which are predominantly downregulated 
in APP/PS1dE9/apoE3-TR mice, when compared with 
apoE3-TR mice, in response to bexarotene treatment (74). 
Importantly, this work highlights how the genetic program 
modulated by NR agonists might change in the context of 
AD, in comparison to a nonpathological state.
Recently, it was reported that activation of LXRs in a tri-
ple transgenic mouse model of AD (3xTg-AD) leads to a 
change in the DNA methylation status of genes related to 
synaptic function (Syp, Syn1, and Dlg3) and neurogenesis 
(Hmgb3 and Rbbp7), suggesting an increase in their expres-
sion, which was, in fact, confirmed for Syn1 (76). These 
results are in line with previous work published by the same 
authors, demonstrating  that  the beneficial  effect of LXR 
on synaptic function in 3xTg-AD mice is dependent on 
synaptic-related protein synthesis, which is disrupted by A 
(77). Another recent study reported that the activation of 
PPAR by simvastatin is able to improve memory function 
in 5XFAD mice, which is likely underlined by an increase 
in cAMP-response element binding protein (CREB) and 
brain-derived neurotrophic factor (34). Moreover, it has 
been shown that PPAR activation by rosiglitazone rescues 
cognitive deficits in a Tg2576 AD mouse model, but it does 
not affect WT mouse performance, which was proposed to 
be underlined by a normalization of a dysregulated mito-
gen-activated protein kinase (ERK) signaling pathway in 
AD brains (78, 79). Further study of this mechanism led to 
the suggestion that PPAR activation is able to restore 
memory consolidation in AD animals through an interac-
tion with phosphorylated ERK in a multiprotein complex, 
including mitogen-activated protein kinase kinase (MEK) 
and ribosomal S6 kinase -1 (p90RSK) (80). The authors 
propose a model in which PPAR restores an AD-associ-
ated dysfunction of ERK signaling involved in memory 
consolidation through the recruitment of a multi-protein 
complex, for which a potential partner is suggested to be 
CREB-binding protein (CBP), a cofactor for both CREB 
and PPAR, restoring proper ERK-dependent regulation 
of transcription of target genes involved in memory forma-
tion. This work is in agreement with the observation that 
rosiglitazone normalizes presynaptic function, ameliorates 
aberrant firing, and restores the output function of Tg2576 
mouse dentate gyrus granule cells (81, 82). The authors 
propose that the regulation of different presynaptic vesicu-
lar proteins and potassium and calcium channels by rosigli-
tazone might be an underlying mechanism responsible for 
the beneficial effects of PPAR activation. Furthermore, it 
has also been shown that the activation of PPAR with rosi-
glitazone attenuated the decrease in dendritic filopodia 
and synapse density elicited by A(1-42) in cultured rat 
hippocampal neurons, and it protected hippocampal slices 
from A(1-42)-induced long-term potentiation deficits as 
well (83). These authors observed that A(1-42) induces a 
reduction in the number of mitochondria in neuronal 
dendrites and spines, which is prevented by rosiglitazone; 
thus, it was proposed that this mitochondrial effect might 
be an underlying mechanism by which PPAR activation by 
rosiglitazone prevents A(1-42)-induced deficits in synapse 
formation and plasticity. Moreover, it has been found that 
activation of PPAR and PPAR are also neuroprotective 
against A-induced toxicity. Based on in vitro work, the un-
derlying mechanism is proposed to be related to modula-
tion of Wnt signaling reflected by an increase in -catenin 
and reduction in glycogen synthase kinase-3 activity in 
neurons (84, 85). Moreover, NRs have recently been dem-
onstrated to have direct neuroprotective effects in 5XFAD 
mice,  as  administration  of  the RXR  agonist,  bexarotene, 
resulted in prevention of neuronal loss observed in this 
model, which was accompanied by elevation of both pre- 
and postsynaptic markers and behavioral improvement 
(86). Similarly, the PPAR/ agonist, GW0742, has also 
been shown to have a neuroprotective effect in the 5XFAD 
model, particularly preventing neuronal loss in the subicu-
lum (87). RARs have also been shown to be neuroprotec-
tive, driving the expression of brain-derived neurotrophic 
factor when activated, although not in an AD setting (88).
CLINICAL TRIALS
Although the animal studies are very promising, the 
clinical efficacy of NR activation in AD has yet to be demon-
strated. A phase III trial to test the PPAR agonist, rosigli-
tazone, as monotherapy in mild to moderate AD failed to 
show clinical efficacy (89), which may be related to the 
poor brain penetrance of this drug. Recently, Takeda and 
Zinfandel Pharmaceuticals initiated a phase III trial to test 
the efficacy of the PPAR agonist, pioglitazone, in AD, and 
this trial is currently underway. Additionally, Heneka, Fink, 
and Doblhammer (90) found that chronic treatment of dia-
betic patients with pioglitazone is associated with a reduc-
tion of dementia risk by 47%, through analysis of data 
obtained from the German health insurance registry over a 
period of 6 years, suggesting a neuroprotective effect. Cum-
mings et al. (91) have recently reported the outcome of a 
small phase II trial of the RXR ligand, bexarotene, in AD 
patients. The trial, involving a 30 day treatment of mild to 
moderate AD patients, reported a significant decrease in 
brain amyloid burden in APOE4 noncarriers accompanied 
by a concomitant increase in the levels of serum A(1-42), 
suggesting an increased clearance of A from the brain to 
the periphery. There was no change in amyloid burden in 
APOE4 carriers. The study was not powered to assess cogni-
tion. Importantly, bexarotene treatment caused a significant 
elevation of serum triglycerides, which may represent a car-
diovascular risk for the patients. A phase Ib trial was also 
performed in healthy subjects, homozygous for the APOE3 
allele, to determine whether bexarotene could modulate 
apoE and A levels in these subjects (92). This drug modestly 
increased apoE levels in cerebrospinal fluid and failed to 
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reduce A levels, which was attributed to the poor penetra-
tion of bexarotene into the CNS, which might hamper the 
utility of this drug in clinical practice. It is noteworthy that 
bexarotene effects depend on the APOE genotype, which 
might warrant further investigation.
CONCLUSIONS
The activation of NRs seems to be a promising therapeu-
tic strategy for AD; however, the mechanisms underlying 
the salutary effects of NRs are still not fully understood. 
The identification of the precise mechanisms that are regu-
lated by these NRs could open the door for novel and more 
targeted pharmacological interventions directed at new 
therapeutic targets. Furthermore, it is also important to 
keep in mind the systemic effects of NR agonists, their 
pharmacodynamics, and brain penetrance, as these types 
of drugs are considered for use in CNS disorders. A more 
detailed characterization of the pathophysiological mecha-
nisms in AD is also warranted, especially as new players are 
being identified, such as the case of infiltrating monocytes. 
Moreover, targeting different classes of NRs, such as estrogen 
receptors, might also be of therapeutic interest for AD.
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